We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement
Analytical Cannabis Logo
×

Psychedelics in Psychiatry

02 Sep 2021 at 16:00 UTC

Psychedelics in Psychiatry

Who's speaking at this Webinar?

Prof. Matthew Johnson, PhD
Professor of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine
 

A body of empirical research has emerged over the last couple of decades suggesting that the 5-HT2A receptor agonist classic psychedelic compound psilocybin results in positive long term outcomes in both healthy participants and in individuals with psychiatric disorders. This research has been conducted under conditions of substantial preparation, and interpersonal support. Findings have suggested that under such conditions psilocybin leads to increased personality openness in healthy participants, decreased depression and anxiety in cancer patients, and increased biologically-confirmed quit rates in treatment-resistant tobacco cigarette smokers. These findings are consistent with the notion that psychedelic therapy is best thought of as medication-assisted behavioral or psychological therapy, wherein the drug increases behavioral plasticity, providing an experience that can influence future behavior. A vision will be presented suggesting that psychedelics may be leveraged in the treatment of a variety of nominally distinct psychiatric disorders.

During this webinar we will discuss:

  • Research suggesting psilocybin results in positive long term outcomes in both healthy participants and in individuals with psychiatric disorders.
  • How psychedelics may be leveraged in the treatment of a variety of nominally distinct psychiatric disorders.

Watch Now
 

Stay connected with the latest news in cannabis extraction, science and testing

Get the latest news with the FREE weekly Analytical Cannabis newsletter

 
Advertisement